Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

UBS analyst Ashwani Verma raised the firm’s price target on United Therapeutics (UTHR) to $415 from $385 and keeps a Buy rating on the shares. UBS ...

Looking at United Therapeutics’s peers in the therapeutics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. BioMarin Pharmaceutical delivered year ...

Liquidia lands major victory in patent dispute with United Therapeutics Unlock URL Order Reprints Gift this Article ...

United Therapeutics achieves 12th consecutive quarter of growth, fueled by Tyvaso success. Discover insights on upcoming catalysts & $1B share buyback.

United Therapeutics ( NASDAQ: UTHR) has entered into two accelerated share repurchase deal to buy back an aggregate of $1 billion of its common stock. The company will repurchase these shares as part ...

In addition, United Therapeutics and Miromatrix file annual, quarterly and current reports and other information with the SEC, which are available to the public from commercial document-retrieval ...

United Therapeutics added that “ [b]oth parties have the opportunity to request rehearing by the Federal Circuit with respect to the adverse portions of the Federal Circuit’s affirmance.” ...

United Therapeutics Issues its 2023 Corporate Responsibility and Public Benefit Report Report available at corporateresponsibility.unither.com September 12, 2023 06:00 AM Eastern Daylight Time ...

Rothblatt's team at United Therapeutics has transplanted genetically edited organs from pigs into humans. In September 2021, the first pig-kidney transplant functioned in a brain-dead human.

United Therapeutics is up 3.8% during the same time and is heading into earnings with an average analyst price target of $380.98 (compared to the current share price of $298.14).

United Therapeutics will commence a tender offer to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing (an aggregate of approximately $91 ...